Bruker Corporation $BRKR Position Cut by Bank of New York Mellon Corp

Bank of New York Mellon Corp lowered its holdings in shares of Bruker Corporation (NASDAQ:BRKR) by 2.4% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 899,042 shares of the medical research company’s stock after selling 22,266 shares during the period. Bank of New York Mellon Corp’s holdings in Bruker were worth $37,041,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Envestnet Asset Management Inc. raised its stake in shares of Bruker by 7.3% during the first quarter. Envestnet Asset Management Inc. now owns 380,096 shares of the medical research company’s stock valued at $15,865,000 after purchasing an additional 25,990 shares in the last quarter. Allworth Financial LP increased its stake in Bruker by 92.4% during the 1st quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after buying an additional 364 shares during the period. State of Michigan Retirement System raised its position in shares of Bruker by 1.1% during the 1st quarter. State of Michigan Retirement System now owns 26,493 shares of the medical research company’s stock worth $1,106,000 after buying an additional 300 shares in the last quarter. Xponance Inc. lifted its stake in shares of Bruker by 1.8% in the 1st quarter. Xponance Inc. now owns 22,325 shares of the medical research company’s stock worth $932,000 after acquiring an additional 394 shares during the period. Finally, Louisiana State Employees Retirement System boosted its holdings in shares of Bruker by 1.0% in the first quarter. Louisiana State Employees Retirement System now owns 31,000 shares of the medical research company’s stock valued at $1,294,000 after acquiring an additional 300 shares in the last quarter. Institutional investors own 79.52% of the company’s stock.

Bruker Trading Up 1.8%

Shares of BRKR opened at $42.49 on Thursday. The business’s 50-day moving average price is $35.59 and its 200 day moving average price is $37.14. The company has a current ratio of 1.61, a quick ratio of 0.70 and a debt-to-equity ratio of 1.31. The stock has a market capitalization of $6.46 billion, a P/E ratio of 81.71, a P/E/G ratio of 5.31 and a beta of 1.26. Bruker Corporation has a 1-year low of $28.53 and a 1-year high of $64.64.

Bruker (NASDAQ:BRKR) last posted its quarterly earnings data on Monday, November 3rd. The medical research company reported $0.45 EPS for the quarter, beating analysts’ consensus estimates of $0.33 by $0.12. The company had revenue of $860.50 million during the quarter, compared to analyst estimates of $847.40 million. Bruker had a net margin of 2.31% and a return on equity of 17.89%. The business’s quarterly revenue was down .5% on a year-over-year basis. During the same period in the prior year, the firm earned $0.60 earnings per share. Bruker has set its FY 2025 guidance at 1.850-1.90 EPS. Analysts expect that Bruker Corporation will post 2.69 earnings per share for the current year.

Bruker Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 2nd. Shareholders of record on Monday, December 8th will be given a dividend of $0.05 per share. This represents a $0.20 annualized dividend and a yield of 0.5%. The ex-dividend date is Monday, December 8th. Bruker’s payout ratio is presently -125.00%.

Insider Activity at Bruker

In other news, Director Cynthia M. Friend sold 3,535 shares of the firm’s stock in a transaction on Friday, September 12th. The stock was sold at an average price of $32.25, for a total value of $114,003.75. Following the completion of the sale, the director owned 18,016 shares of the company’s stock, valued at $581,016. This trade represents a 16.40% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director John A. Ornell sold 6,233 shares of the company’s stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $39.00, for a total value of $243,087.00. Following the transaction, the director directly owned 35,212 shares in the company, valued at $1,373,268. The trade was a 15.04% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 27.30% of the company’s stock.

Analysts Set New Price Targets

BRKR has been the topic of several recent analyst reports. Weiss Ratings reissued a “sell (d+)” rating on shares of Bruker in a report on Wednesday, October 8th. UBS Group boosted their price objective on Bruker from $40.00 to $43.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 4th. Stifel Nicolaus set a $40.00 price objective on Bruker and gave the company a “hold” rating in a report on Tuesday, August 5th. Barclays raised their target price on Bruker from $40.00 to $45.00 and gave the company an “overweight” rating in a research note on Tuesday, November 4th. Finally, TD Cowen upped their price target on shares of Bruker from $40.00 to $42.00 and gave the company a “hold” rating in a report on Tuesday, November 4th. Five investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $48.30.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.